Delhi HC Sets Aside Patent Refusal on Recombinant Polypeptide Claims: Section 3(c) Practitioner Takeaways from Pioneer Hi-Bred v. Controller

Delhi HC Sets Aside Patent Refusal on Recombinant Polypeptide Claims: Section 3(c) Practitioner Takeaways from Pioneer Hi-Bred v. Controller
Justice Jyoti Singh of the High Court of Delhi has, by order dated 22 July 2026 in C.A.(COMM.IPD-PAT) 35/2024, Pioneer Hi-Bred International Inc. v. The Controller of Patents, set aside the Patent Office's refusal of claims directed to a recombinant polypeptide. The decision sits at the head of the contemporary Section 3(c) polypeptide cluster on Indian Kanoon and establishes that an invention framed around a process step recombinant plasmid insertion into a plant host followed by host-engineered expression cannot be reduced to a "merely discovered" substance within the meaning of Section 3(c) of the Patents Act, 1970. For pharma R&D heads, plant-biotech patent prosecutors, and in-house biotech IP counsel, Pioneer sharpens the doctrinal threshold at which Section 3(c) no longer attaches.
The decision matters beyond the parties' particular polypeptide estate because it draws the line on process-claim recitations, not on the product-of-nature framing that has driven a decade of Patent Office refusals on Section 3(c).
Why the Pioneer Ruling Matters for Pharma and Biotech
Recombinant polypeptides underwriting insulin, erythropoietin, monoclonal antibodies, Bt-crop δ-endotoxins, and the modern therapeutic peptide class all frame Indian claims around a process or recombinant expression pathway rather than around an isolated end product. The Patent Office's discretionary refusal record over the last decade has treated Section 3(c) as the gating bar claims framed as a "mere polypeptide occurring in nature" or a "naturally occurring amino acid sequence" have routinely come back with the "substance occurring in nature" stamp. Pioneer re-pivots the analysis onto the process step: if the claim recites a recombinant transformation requiring human intervention at the molecular level plasmid insertion, host expression, post-translational processing the inventor has crossed from "discovery" to "manufacture," and Section 3(c) no longer attaches.
This reframing has downstream consequences for Section 3(d) analysis, though Section 3(c) remains doctrinally distinct. Section 3(d) controls "any new form of a known substance which does not result in enhancement of known efficacy" (the Novartis v. Union of India, Supreme Court, 2013 lane); Section 3(c) controls "mere discovery of any living thing or non-living substance occurring in nature." A composition claim may run into both bars simultaneously natural-origin grounds (3(c)) and known-substance grounds (3(d)). Pioneer gives the Section 3(c) side a process-recital safe harbour that the Novartis analysis rarely offers on the Section 3(d) side; Indian prosecutors should plead both bars as alternative grounds rather than as a single integrated refusal contest.
What the Court Actually Held
The Bench (Justice Jyoti Singh, sitting single) set aside the Patent Office's refusal and remitted the application for fresh consideration under proper statutory framing. Three lines of reasoning structure the order:
- Structural Transformation Over Natural Origin: Claims directed to a recombinant δ-endotoxin polypeptide expressed in a plant host cannot be treated as a "discovery of a substance occurring in nature" because the recombinant transformation operates on the substrate's structural identity the cell's translation apparatus, post-translational processing, and host-internal folding produce a polypeptide whose conformation is not the natural-occurring lineage form.
- Misdirection on the Statutory Threshold: The Patent Office's refusal focused exclusively on Section 3(c) "mere discovery" without evaluating whether the recombinant process produced a changed structural form or whether the host expression step altered the natural substrate across definitional lines. The Court characterised that omission as a misdirection on the statutory threshold.
- Applicability of Section 3(j) Carve-Outs: The refusal failed to consider whether the underlying process was "essentially biological" within the meaning of Section 3(j), a separate bar operating on process claims. The Court treated the recombinant plasmid insertion as a non-biological, human-directed step that takes the manufacturing process outside Section 3(j)'s essentially-biological-process bar.
On the procedural side, the Court set aside the refusal rather than issuing a grant direction, leaving the Patent Office free to take the application back into examination under the corrected statutory framing.
Section 3(c) and the Mere-Discovery Floor
Section 3(c) of the Patents Act, 1970 bars patents for "the mere discovery of any living thing or non-living substance occurring in nature." The bar has been read narrowly against biologically-derived material since Dimminaco A.G. v. The Controller of Patents & Designs (Calcutta High Court, 15 January 2002, (2002) I.P.L.R. 255). The Calcutta HC in Dimminaco interpreted the definition of "manufacture" within Section 2(1)(j) of the Patents Act, 1970, holding that a process yielding a vendible product containing a living virus (an attenuated or inactivated vaccine) constitutes patent-eligible manufacture not a "mere discovery." Practitioners run Dimminaco's "human intervention transforming a natural substrate into a vendible product" principle alongside the Section 3(c) statutory bar: Dimminaco establishes that the process yields a manufacture within the Section 2(1)(j) definition of "invention"; the Section 3(c) argument establishes that the manufacture is not "merely discovered" within the meaning of Section 3(c). Both prongs run together against the refusal; neither alone is the complete defense.
Dimminaco A.G. v. Controller (Cal HC, 15 January 2002, (2002) I.P.L.R. 255) is the doctrinal anchor for the proposition that human intervention transforming a natural substrate into a vendible product places the invention within Section 2(1)(j)'s definition of "manufacture" and once that threshold is satisfied, the Section 3(c) bar is reframed as a question of whether the manufacture is "merely" the natural substrate or whether it is a different structural entity produced by the human step. Practitioners should plead Dimminaco as the in-house precedent on Section 2(1)(j), with Section 3(c) framed as the complementary inquiry into "mere-ness"; any subsequent Delhi HC order treating Dimminaco as binding precedential authority will lean on the Calcutta HC reasoning without modifying the substantive test. The operative principle is unchanged across two decades of Patent Office practice: a process yielding a vendible product containing a structurally-altered substrate is patent-eligible manufacture under Section 2(1)(j), and the Section 3(c) bar falls away once the human-step / structurally-altered-substrate threshold is crossed by reference to that manufacture.
The closest US comparative authority is Amgen Inc. v. Sanofi, 598 U.S. 594 (2023) (decided 18 May 2023 by the US Supreme Court, Justice Gorsuch writing for a unanimous Court). The US Supreme Court held that broad functional genus claims to a class of antibodies must satisfy the enablement requirement of 35 U.S.C. §112(a) with reasonably specific instructions covering the full scope of the claimed genus. Amgen is instructive as a comparative reference on the enablement and written-description demands for genus claims, but the Indian doctrine does not import US enablement-side framing into the Section 3(c) threshold. The Indian analysis sits on whether the recombinant step alters structural identity a different doctrinal axis from US enablement.
Section 3(j) on the Bare Statutory Text
Section 3(j) bars patents for "plants and animals in whole or in any part thereof other than micro-organisms but including seeds, varieties and species, and essentially biological processes for production of plants or animals, other than non-biological and microbiological processes for the production of plants or animals." Read on the bare statutory text, the recombinant process at issue in Pioneer satisfies the carve-out. Plasmid insertion into a plant host is a human-directed molecular intervention, not propagation or breeding; the host's translation machinery is a passive substrate for the human step, not a "biological" process in the sense Section 3(j) uses the term. The production pathway is microbiological in the same sense that fermentation or bacterial expression is microbiological. Section 3(j) does not fire on a recombinant DNA plasmid-insertion pathway; the bar applies to breeding, selection, and propagation-driven processes where the human step directs conjugation, segregation, or natural-occurrence selection rather than molecular engineering.
Practical implication: A patent application claiming a recombinant polypeptide per se (composition framing) or a method for producing a recombinant polypeptide (process framing) is, on the Pioneer reasoning, prima facie patent-eligible under Section 3(j)'s non-biological/microbiological carve-out. Patent prosecutors should anchor Indian claims on the process step when the inventive contribution rides on the recombinant transformation itself; composition claims without a process recitation remain vulnerable on bare Section 3(c) grounds.
The Procedural Frame Under the Patents (Amendment) Rules, 2024
A polypeptide application that survives Section 3(c) on Pioneer's reasoning still has to walk through the procedural regime set by the Patents (Amendment) Rules, 2024 notified 15 March 2024. Four procedural anchors are critical:
- Form 5 (Declaration as to Inventorship) under Section 7 read with Rule 13(6): Declare all inventors who contributed to the recombinant transformation step. The bar on naming a person "who merely sequences a known molecule" is not implicated where the inventor's contribution is the recombinant plasmid insertion or the host engineering. Declarations of independent claim authorship for the molecular and process-step inventors are advisable.
- Form 18 (Request for Examination) under Section 11B read with substituted Rule 24B(1): The examination-request deadline is 31 months from the priority date or from the date of filing of the application, whichever is earlier, for applications filed on or after 15 March 2024. The 48-month cycle is operative only for applications filed before 15 March 2024 (transitional protection under the proviso to substituted Rule 24B(1)). Failure to file Form 18 within the deadline results in the application being treated as withdrawn by the applicant under the exact statutory term of Section 11B(4) the phrase "deemed abandoned" is reserved for Section 21(1) prosecution deadlines.
- Sequence Listing under Patent Rule 13A: As substituted under the 2024 Rules, Indian sequence listing requirements align with the PCT Rule 5.2 / WIPO ST.26 XML standard. Sequence listings filed in pre-2024 format face supplementary listing obligations during examination; new filings should produce the WIPO ST.26 XML record from the international phase.
- Budapest Treaty Deposit under Section 10(4)(d)(ii) read with Rule 13(8): Where the recombinant host or the polypeptide is deposited with a recognised depository (MTCC Chandigarh, IDA Ireland, ATCC USA, DSMZ Germany), the biological material must be deposited no later than the date of filing of the Indian application (or no later than the international filing date for PCT national-phase applications), and the reference to such deposit must be included in the specification within 3 months from the date of filing in India under Rule 13(8). The deposit cutoff is at the date of filing not at the 31-month examination-request deadline, not at the publication date, and not at the Section 11B(4) deadline. Where the application enters India via PCT national phase and the international record already discloses the deposit, the deposit reference can be carried into the India record within the 3-month Rule 13(8) window without re-depositing.
Navigating Condonation and Dual 31-Month Clocks
- Rule 138 condonation read with Form 4: This provides a discretionary route for delays up to six months beyond the 31-month examination-request deadline. Rule 138 is broadly discretionary but is not routine practitioners should not assume the Controller will condone a missed Form 18 deadline as a simple cure. Where the missed 31-month deadline is on the substituted Rule 24B(1) (Form 18) examination-request track specifically, Rule 138 condonation interacts with the Section 11B(4) "treated as withdrawn" trigger in a complex manner: condonation may revive the application, but the published Section 11B(4) consequence has already run and may have created downstream prior-art or opposition-side complications in family members.
- Do not confuse the two 31-month clocks in the 2024 regime: The Form 18 / substituted Rule 24B(1) examination-request deadline is 31 months from priority or filing, with a six-month Rule 138 condonation tail available. The PCT national-phase entry deadline under Rule 20(4) remains 31 months from the priority date (or from the international filing date only where no priority is claimed), was not substituted by the 2024 Rules, and is not subject to Rule 138 condonation in the same way because the PCT Articles 22 and 39 timelines operate transnationally. The two clocks have the same priority-date reckoning event by default but different procedural triggers Form 18 / Rule 24B(1) governs the examination request, Rule 20(4) governs the national-phase entry itself and different downstream consequences.
Implications for In-House IP Counsel
- Anchor claim drafting on the recombinant process step. When the inventive contribution rides on host engineering or the recombinant transformation itself, frame the independent claim as a process claim; frame the dependent claims as compositions-of-matter claims on the polypeptide product. Pioneer gives the process-anchor a Section 3(c) safe harbour that collapses the Patent Office's natural-origin objection for compositions drafted in isolation. A composition-only claim without a process recitation remains vulnerable.
- Align the Form 18 deadline at the international phase. The substituted Rule 24B(1) 31-month Form 18 clock starts from the priority date for PCT national-phase applications, that is exactly the same pre-arrival clock the PCT national-phase team has been managing under Rule 20(4). Aligning the Indian Form 18 deadline with the PCT Rule 20(4) 31-month-from-priority reckoning event avoids a dual-deadline management overhead.
- Build Budapest deposit + sequence listing into the WIPO ST.26 record at the international phase. If the application enters India via PCT national phase, align the Indian sequence listing with the WIPO ST.26 XML record from the international phase rather than re-drafting it for India protection. The patent attorney of record at the designated/elected Office (the Indian Patent Office) can lean on the international-phase record without re-substantiating Form 5 inventorship or re-depositing biological material that was already deposited under the Budapest Treaty on or before the international filing date.
Frequently Asked Questions (FAQs)
Does the Pioneer ruling relax Section 3(c) for natural-product polypeptide claims broadly?
No. Pioneer draws the line at the recombinant transformation, not at any "polypeptide in nature" line. A claim on a polypeptide framed as an isolated natural product, without a recombinant or fermentation process anchor, remains squarely inside the Section 3(c) bar. The Patent Office continues to apply Section 3(c) on natural-origin grounds to thinly drafted polypeptide claims Pioneer does not change that. The decision sharpens the threshold; it does not eliminate the bar.
Does Pioneer open a back door past Section 3(d) on known-substance grounds?
No. Section 3(d) operates independently of Section 3(c). A recombinant-polypeptide application that survives Section 3(c) on the Pioneer reasoning still has to clear the Section 3(d) enhancement-of-known-efficacy test as the Supreme Court articulated it in Novartis v. Union of India (2013). The two bars are not substitutes. Patent prosecutors should plan to address both bars separately during prosecution a favourable Pioneer-style Section 3(c) reframing does not shortcut the Section 3(d) analysis.
Should we refile Indian patent claims directed to isolated polypeptides that were refused on Section 3(c) grounds?
In specific cases where the international-phase or PCT family member describes the recombinant process step clearly, a controlled re-filing with primary focus on the process claim and a Section 2(1)(j) novelty amendment may be viable. The risk profile is high refiling sacrifices priority and resurrects opposition windows and the practitioner should weigh the Section 3(c) analysis carefully before initiating. Pioneer is at this point a single-refusal decision at the head of a narrow line of authority, and an Appellate Bench may revisit its scope once contested. Without a process recitation in the family record, a re-filing does not benefit from the Pioneer reasoning and the prior Section 3(c) refusal will re-execute on the same grounds.